190 related articles for article (PubMed ID: 30316610)
41. Nivolumab and its use in the second-line treatment of metastatic urothelial cancer.
Raggi D; Necchi A; Giannatempo P
Future Oncol; 2018 Nov; 14(26):2683-2690. PubMed ID: 29927336
[TBL] [Abstract][Full Text] [Related]
42. Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study.
Vassilakopoulou M; de la Motte Rouge T; Colin P; Ouzzane A; Khayat D; Dimopoulos MA; Papadimitriou CA; Bamias A; Pignot G; Nouhaud FX; Hurel S; Guy L; Bigot P; Roumiguié M; Rouprêt M;
Cancer; 2011 Dec; 117(24):5500-8. PubMed ID: 21638278
[TBL] [Abstract][Full Text] [Related]
43. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for poor prognosis patients with urothelial tumors and effect of dose intensity.
Hibi H; Okamura K; Takashi M; Shimoji T; Miyake K
Hinyokika Kiyo; 1997 Feb; 43(2):89-96. PubMed ID: 9086342
[TBL] [Abstract][Full Text] [Related]
44. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.
Galsky MD; Chen GJ; Oh WK; Bellmunt J; Roth BJ; Petrioli R; Dogliotti L; Dreicer R; Sonpavde G
Ann Oncol; 2012 Feb; 23(2):406-10. PubMed ID: 21543626
[TBL] [Abstract][Full Text] [Related]
45. Biomarker challenges for immune checkpoint inhibitors in urothelial carcinoma.
Powles T; Morrison L
Nat Rev Urol; 2018 Oct; 15(10):585-587. PubMed ID: 30030491
[No Abstract] [Full Text] [Related]
46. Chemotherapy of urothelial tract tumors.
Yagoda A
Cancer; 1987 Aug; 60(3 Suppl):574-85. PubMed ID: 3297286
[TBL] [Abstract][Full Text] [Related]
47. Recent Clinical Trials Explore Immunotherapies for Urothelial Carcinoma.
Balar AV
Oncology (Williston Park); 2019 Apr; 33(4):132-6. PubMed ID: 30990565
[No Abstract] [Full Text] [Related]
48. Prognostic factors for metastatic urothelial carcinoma undergoing cisplatin-based salvage chemotherapy.
Taguchi S; Nakagawa T; Hattori M; Niimi A; Nagata M; Kawai T; Fukuhara H; Nishimatsu H; Ishikawa A; Kume H; Homma Y
Jpn J Clin Oncol; 2013 Sep; 43(9):923-8. PubMed ID: 23888082
[TBL] [Abstract][Full Text] [Related]
49. Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinoma.
Tang Q; Li S; Huang G; Liu H
Int Immunopharmacol; 2023 Jun; 119():110158. PubMed ID: 37062259
[TBL] [Abstract][Full Text] [Related]
50. Carboplatin and vinblastine for the treatment of metastatic transitional cell carcinoma of the urothelial tract.
Al-Karim HA; Tan KE; Chi KN; Bryce CJ; Murray NR; Coppin C
Am J Clin Oncol; 2002 Oct; 25(5):515-9. PubMed ID: 12393996
[TBL] [Abstract][Full Text] [Related]
51. Cisplatin combination chemotherapy for elderly patients with urothelial tumours.
Sella A; Logothetis CJ; Dexeus FH; Amato R; Finn L; Fitz K
Br J Urol; 1991 Jun; 67(6):603-7. PubMed ID: 2070205
[TBL] [Abstract][Full Text] [Related]
52. Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: a phase II study.
Kim J; Millikan RE; Smith TL; Tu SM; Pagliaro LC; Logothetis CJ
Urol Oncol; 2003; 21(1):21-6. PubMed ID: 12684123
[TBL] [Abstract][Full Text] [Related]
53. [Not Available].
Thibault C
Bull Cancer; 2018 Dec; 105 Suppl 1():S43-S49. PubMed ID: 30595198
[TBL] [Abstract][Full Text] [Related]
54. Is there a role for maintenance therapy after platinum chemotherapy in bladder cancer in the era of immune therapy?
Rassy E; Assi T; Kattan J
Future Oncol; 2019 Dec; 15(34):3877-3879. PubMed ID: 31729240
[No Abstract] [Full Text] [Related]
55. Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer.
Stühler V; Maas JM; Bochem J; da Costa IA; Todenhöfer T; Stenzl A; Bedke J
World J Urol; 2019 Sep; 37(9):1773-1784. PubMed ID: 30374610
[TBL] [Abstract][Full Text] [Related]
56. [PPA (cis-platinum), peplomycin and adriamycin) combination chemotherapy in transitional cell carcinoma of the urothelial tract--pilot study].
Ono Y; Ohshima S; Fujita T; Naide Y; Suzuki K; Asoh Y; Fukushima M; Ohta K
Nihon Gan Chiryo Gakkai Shi; 1986 Feb; 21(1):28-33. PubMed ID: 2422307
[No Abstract] [Full Text] [Related]
57. Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy.
Gerullis H; Eimer C; Ecke TH; Georgas E; Arndt C; Otto T
Anticancer Drugs; 2013 Apr; 24(4):422-5. PubMed ID: 23407060
[TBL] [Abstract][Full Text] [Related]
58. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial.
Twardowski P; Stadler WM; Frankel P; Lara PN; Ruel C; Chatta G; Heath E; Quinn DI; Gandara DR
Urology; 2010 Oct; 76(4):923-6. PubMed ID: 20646741
[TBL] [Abstract][Full Text] [Related]
59. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
60. Complete response to tislelizumab in a metastatic urothelial carcinoma after surgery associated with high tumor mutational burden: a case report.
Jin J; Yang Q; Yu Y; Chen L; Pan S
Anticancer Drugs; 2023 Apr; 34(4):595-598. PubMed ID: 36730313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
